Literature DB >> 12591818

The primacy of clinical effectiveness for cost effectiveness analysis.

I P Casserly, E J Topol.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12591818      PMCID： PMC1767603          DOI： 10.1136/heart.89.3.249

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  14 in total

1.  Medical economics and the assessment of value in cardiovascular medicine: Part I.

Authors:  Daniel B Mark; Mark A Hlatky
Journal:  Circulation       Date:  2002-07-23       Impact factor: 29.690

2.  Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group.

Authors:  B Lindahl; P Venge; L Wallentin
Journal:  Circulation       Date:  1996-05-01       Impact factor: 29.690

3.  Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

Authors:  W Klein; A Buchwald; S E Hillis; S Monrad; G Sanz; A G Turpie; J van der Meer; E Olaisson; S Undeland; K Ludwig
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

4.  Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.

Authors:  J W Eikelboom; S S Anand; K Malmberg; J I Weitz; J S Ginsberg; S Yusuf
Journal:  Lancet       Date:  2000-06-03       Impact factor: 79.321

5.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).

Authors: 
Journal:  Eur Heart J       Date:  1999-11       Impact factor: 29.983

6.  Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial.

Authors:  M Janzon; L-A Levin; E Swahn
Journal:  Heart       Date:  2003-03       Impact factor: 5.994

7.  Reactivation of unstable angina after the discontinuation of heparin.

Authors:  P Théroux; D Waters; J Lam; M Juneau; J McCans
Journal:  N Engl J Med       Date:  1992-07-16       Impact factor: 91.245

8.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

Authors:  E M Antman; C H McCabe; E P Gurfinkel; A G Turpie; P J Bernink; D Salein; A Bayes De Luna; K Fox; J M Lablanche; D Radley; J Premmereur; E Braunwald
Journal:  Circulation       Date:  1999-10-12       Impact factor: 29.690

9.  Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.

Authors:  P A Merlini; K A Bauer; L Oltrona; D Ardissino; M Cattaneo; C Belli; P M Mannucci; R D Rosenberg
Journal:  Circulation       Date:  1994-07       Impact factor: 29.690

10.  Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.

Authors: 
Journal:  Lancet       Date:  1996-03-02       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.